Human Anti-DENV4 E Recombinant Antibody (clone DV22) (CAT#: FAMAB-1692CQ)

Figure 1 Three mAbs neutralize all four DENV serotypes by binding two distinct epitopes on each virus.

Three mAbs (all IgG1) were selected for their specificity and neutralizing activity: DV87.1 binds DIII of DENV-1, −2 and −3; DV22.3 binds DI/DII of DENV-4, and DV82.11 cross-reacts with DI/DII of all DENV serotypes. (A) Neutralization (○) and enhancement (●) of infection by recombinant unmodified mAbs. (B) Neutralization (○) and enhancement (●) of infection by engineered LALA variant mAbs. Nonlinear regression analysis was used to calculate the EC50, indicated in the panel. Data are mean of duplicates. One representative experiment out of three performed. (C) A cocktail of LALA-mAbs (DV82.11= 2 µg/ml, DV87.1=DV22.3= 0.2 µg/ml) was used in combination with mAbs directed against prM (DV69.6) or DI/DII E protein (DV78.6) or serum from a primary DENV-infected donor at potent enhancing concentration (0.1 µg/ml) on K562 cells.

Beltramello, M., Williams, K. L., Simmons, C. P., Macagno, A., Simonelli, L., Quyen, N. T. H., ... & Sallusto, F. (2010). The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell host & microbe, 8(3), 271-283.